Inflammatory Bowel Disease
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
NCT00810030 | PHASE 3 | INTERVENTIONAL
The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
AKH Vienna, University clinic of Int Medizin III
Vienna,Austria,1090
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov